Ignacio Melero: "La búsqueda de eficacia y de biomarcadores en inmuno-oncología"

21/03/2019

Dr. Melero started out in biomedical research as a resident of immunology at the prestigious department of this specialty in Hospital Universitario de la Princesa (Madrid). He completed his doctoral thesis with Professor Miguel López-Botet identifying and functionally studying natural killer cell receptors. His work obtained the Outstanding Doctorate Award. In 1994 he joined Bristol Myers Squibb Company as a researcher in cancer immunotherapy in his institute in Seattle (WA). The result of his three years of work in this environment are pioneering publications in the knowledge of costimulation of antitumor immune responses and the use of immunostimulatory monoclonal antibodies. During this period, he worked with Professor Lieping Chen in the division led by Professor Karl E. Hellström. In 1998 he returned to Spain in the field of CIMA and Clínica Universidad de Navarra. In these centers he has led a multidisciplinary team working in cancer immunotherapy with cell therapy techniques, gene therapy and monoclonal antibodies. Dr. Melero is full professor of immunology at the University of Navarra, has directed 12 PhD thesis (6 of them obtained the Outstanding Doctorate Award), and has been principal researcher in over 30 clinical trials of immunotherapy (both sponsored by industry and by the center itself). His work has resulted in three patents transferred to industry. From a bibliometric point of view, Dr. Melero has an h-index of 54 and 223 articles indexed in Medline. For his career he has been awarded the BIAL Medicine award (2004), Conde de Cartagena Award of the Royal Academy of Medicine (2006) and Dr. Durantez award of the LAIR Foundation (2011), among other honors. In 2015he was appointed director of the Immunology and Immunotherapy department of the Clínica Universidad de Navarra and in 2018 he was appointed Corresponding member of the Royal Nacional Academy of Medicine. The phrase that best defines Dr. Melero s scientific biography is Translational Research in Cancer Immunotherapy in collaboration with pharmaceutical industry and with european groups receiving funding in consortia for the development of therapeutic strategies.

Vídeos
Ciencias de la vida y de la materia Oncología personalizada de precisión

Eduardo Díaz Rubio: "Lección Magistral: Estrategias de tratamiento en oncología: una perspectiva histórica"

21/03/2019

02carlosarteaga.mp4

Rafael Rosell: "Nuevas dianas terapéuticas en cáncer de pulmón"

21/03/2019

Patrick Tan: "Alteraciones epigenómicas en cánceres endémicos en Asia"

21/03/2019

Manuel Hidalgo: "Nuevos abordajes terapéuticos en cáncer de páncreas"

21/03/2019

Florian Markowetz: "Procesos mutacionales que modulan el número de copias de los genomas del cáncer"

21/03/2019

Santiago Ramón y Cajal: "Heterogeneidad intratumoral: cómo identificarla"

21/03/2019

Pier Paolo Pandolfi: "Reactivación de supresores tumorales en la prevención y terapia del cáncer"

21/03/2019

Enzo Medico: "Oncogenómica y modelos preclínicos derivados del paciente para la medicina de precisión del cáncer colorrectal"

21/03/2019

Ignacio Melero: "La búsqueda de eficacia y de biomarcadores en inmuno-oncología"

21/03/2019

Eric Aboagye: "Imagen molecular y radiómica en la investigación del cáncer: aplicaciones a la oncología de precisión"

21/03/2019

Felipe Calvo: "Radioterapia en la oncología de precisión"

21/03/2019

José Martínez Olmos: "La oncología personalizada de precisión en el Sistema Nacional de Salud"

21/03/2019

Fernando Bandrés: "Consideraciones éticas y legales en la medicina de precisión"

21/03/2019

Paul Workman: "Futuro y sostenibilidad de la investigación en oncología de precisión"

21/03/2019